Synthesis and evaluation of 2,5 and 2,6 pyridine-based CXCR4 inhibitors

被引:18
作者
Gaines, Theresa [1 ]
Camp, Davita [1 ]
Bai, Renren [2 ]
Liang, Zhongxing [2 ,3 ]
Yoon, Younghyoun [3 ]
Shim, Hyunsuk [1 ,2 ]
Mooring, Suazette Reid [1 ]
机构
[1] Georgia State Univ, Dept Chem, Atlanta, GA 30303 USA
[2] Emory Univ, Sch Med, Dept Radiol & Imaging Sci, Atlanta, GA 30322 USA
[3] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
关键词
Pyridine; CXCR4; inhibitor; Matrigel invasion; Binding affinity; Cancer metastasis; Anti-inflammatory; CHEMOKINE RECEPTOR CXCR4; BREAST-CANCER METASTASIS; SMALL-MOLECULE; HUMAN VOLUNTEERS; ANTAGONIST; AMD3100; DISCOVERY; CELLS; AMINES; STORY;
D O I
10.1016/j.bmc.2016.08.018
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Targeting the interaction between G-Protein Coupled Receptor, CXCR4, and its natural ligand CXCL12 is a leading strategy to mitigate cancer metastasis and reduce inflammation. Several pyridine-based compounds modeled after known small molecule CXCR4 antagonists, AMD3100 and WZ811, were synthesized. Nine hit compounds were identified. These compounds showed lower binding concentrations than AMD3100 (1000 nM) and six of the nine compounds had an effective concentration (EC) less than or equal to WZ811 (10 nM). Two of the hit compounds (2g and 2w) inhibited invasion of metastatic cells at a higher rate than AMD3100 (62%). Compounds 2g and 2w also inhibit inflammation in the same range as WZ811 in the paw edema test at 40% reduction in inflammation. These preliminary results are the promising foundation of a new class of pyridine-based CXCR4 antagonists. (C) 2016 Elsevier Ltd. All rights reserved.
引用
收藏
页码:5052 / 5060
页数:9
相关论文
共 32 条
  • [1] Altaf A.A., 2015, A Review on the Medicinal Importance of Pyridine Derivatives, V1, P1, DOI [DOI 10.11648/J.JDDMC.20150101.11, 10.11648/j.jddmc.20150101.11]
  • [2] [Anonymous], 2015, SMALL MOL DRUG DISC
  • [3] [Anonymous], 1995, ACS PROFESSIONAL REF
  • [4] [Anonymous], 2014, SEER CANC STAT REV 1
  • [5] Symmetrical bis-tertiary amines as novel CXCR4 inhibitors
    Bai, Renren
    Liang, Zhongxing
    Yoon, Younghyoun
    Liu, Shuangping
    Gaines, Theresa
    Oum, Yoonhyeun
    Shi, Qi
    Mooring, Suazette Reid
    Shim, Hyunsuk
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2016, 118 : 340 - 350
  • [6] Identification of residues of CXCR4 critical for human immunodeficiency virus coreceptor and chemokine receptor activities
    Brelot, A
    Heveker, N
    Montes, M
    Alizon, M
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (31) : 23736 - 23744
  • [7] Drug Discovery Research Targeting the CXC Chemokine Receptor 4 (CXCR4)
    Choi, Won-Tak
    Duggineni, Srinivas
    Xu, Yan
    Huang, Ziwei
    An, Jing
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (03) : 977 - 994
  • [8] Unique ligand binding sites on CXCR4 probed by a chemical biology approach: Implications for the design of selective human immunodeficiency virus type 1 inhibitors
    Choi, WT
    Tian, SM
    Dong, CZ
    Kumar, S
    Liu, DX
    Madani, N
    An, J
    Sodroski, JG
    Huang, ZW
    [J]. JOURNAL OF VIROLOGY, 2005, 79 (24) : 15398 - 15404
  • [9] The bicyclam AMD3 100 story
    De Clercq, E
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2003, 2 (07) : 581 - 587
  • [10] The AMD3100 story: The path to the discovery of a stem cell mobilizer (Mozobil)
    De Clercq, Erik
    [J]. BIOCHEMICAL PHARMACOLOGY, 2009, 77 (11) : 1655 - 1664